NICE backs AZ’s Forxiga for heart failureJust a few weeks after its EU approval for heart failure, AstraZeneca’s Forxiga has been backed by NICE Share XNICE backs AZ’s Forxiga for heart failurehttps://pharmaphorum.com/news/nice-backs-azs-forxiga-for-heart-failure/
AZ’s Forxiga gets heart claim data on its EU labelAstraZeneca has been cleared to include cardiovascular and kidney outcomes data on the label of its type 2 Share XAZ’s Forxiga gets heart claim data on its EU labelhttps://pharmaphorum.com/news/azs-forxiga-gets-heart-claim-data-on-its-eu-label/
Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerGlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid Share XRelief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerhttps://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/
First-in-class diabetes drug recommended for FDA approvalAstraZeneca and Bristol-Myers Squibb have received a positive opinion from an FDA committee for dapagliflozin, a sodium-glucose cotransporter Share XFirst-in-class diabetes drug recommended for FDA approvalhttps://pharmaphorum.com/news/first-in-class-diabetes-drug-recommended-for-fda-approval/
